• Development Pipeline

Advancing Precision Gene Therapy

Our bio-conjugated AAV platform enables targeted delivery across multiple therapeutic areas, advancing from discovery through clinical development.
Preclinical
BT-001

Neuropathic Pain

Indication

Chronic Neuropathic Pain

Targeting Strategy

Nociceptive sensory neurons

Borea’s conjugated AAV vectors significantly enhance transduction efficiency in nociceptive neurons following peripheral administration. This allows long lasting therapeutic effect at lower doses, paving the way for innovative pain therapies.

Research
BT-002

CNS Disorders

Indication

Central Nervous System Disorders

Targeting Strategy

Brain targeting ligands

Our proprietary conjugation platform enables efficient retrograde transport and tissue barrier crossing across multiple AAV serotypes. The result is enhanced neuronal transduction and a versatile system for CNS-directed therapeutic payloads.

Research
BT-003

Receptor & Ligand Discovery/Design

Indication

Ligand discovery to target specific cells

Targeting Strategy

Borea’s platform combines experimental and computational approaches to discover and validate ligands for precise tissue targeting. Workflow includes scRNASeq analysis to identify enriched genes, selection of cell surface candidates, identification of known ligands or antibodies or de novo in silico design, and testing lead ligands conjugated to AAV via Borea’s click chemistry. Machine learning may support binder design and optimization.

Pipeline

Discovery & PoC
Pre-clinical Development
Phase I
    • PNS Program
    • CNS Program
    • New Programs